Differential Cardiometabolic Risk Profiles of Lean and Obese Metabolic Dysfunction-Associated Steatotic Liver Disease: A Longitudinal Health Checkup Cohort Study.
Oct 2026· Hepatology Research· 0 citations· 14 references
Medicine
TL;DR
Lean MASLD shared a broadly similar cardiometabolic risk structure with Obese MASLD, whereas the relative contribution of risk factors differed between phenotypes, providing exploratory evidence of phenotype-specific metabolic associations requiring validation before clinical application.
Abstract
Background
Lean metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized. Whether it represents a distinct entity or a phenotype within the MASLD spectrum remains unclear. We examined differences in risk factor contribution and metabolic trajectories.
Methods
In a longitudinal health checkup cohort (2017-2025), we included individuals without hepatic steatosis at baseline and excluded those with alcohol intake at or above the MetALD threshold. Incident MASLD was classified at diagnosis as Obese or Lean MASLD based on obesity status (BMI/WC). Baseline risk factors were evaluated using time-to-event and competing-risk models with interaction testing. Longitudinal metabolic changes were assessed using logistic regression, and repeated trajectories were examined using linear mixed-effects models.
Results
Among 13,624 participants, 1865 developed incident MASLD (Obese MASLD, n = 1469; Lean MASLD, n = 396). Male sex, baseline obesity, glycemic abnormality/diabetes, hypertension, hypertriglyceridemia, and higher baseline ALT were independently associated with incident MASLD. Interaction analyses showed a stronger contribution of male sex and weaker contributions of hypertension and low HDL-C in Lean MASLD. Longitudinal analyses showed Δtriglycerides and ΔALT were consistently associated with incident MASLD in both phenotypes, whereas ΔBMI showed a stronger association with Obese MASLD.
Conclusions
Lean MASLD shared a broadly similar cardiometabolic risk structure with Obese MASLD, whereas the relative contribution of risk factors differed between phenotypes. Male sex showed a stronger association with Lean MASLD, whereas longitudinal changes in triglycerides and ALT were consistently associated with incident MASLD across both phenotypes. These findings provide exploratory evidence of phenotype-specific metabolic associations requiring validation before clinical application.
Introduction Metabolic-associated steatotic liver disease (MASLD), newly defined in 2023, is characterized by excessive hepatic triglyceride accumulation in the presence of cardiometabolic risk factors. The body roundness index (BRI), an indicator of body fat distribution and visceral adiposity, has been proposed as a...
BACKGROUND
Metabolic dysfunction-associated steatotic liver disease (MASLD) is prevalent in older adults, yet its independent contribution to cognitive decline beyond cardiometabolic risk factors remains uncertain.
METHODS
We performed a cross-sectional analysis of 1,387 NHANES 2011-2014 participants aged ≥60 years....
Mohammad Aldiabat, Yazan Aljabiri, Wesam Aleyadeh et al.· American Journal of the Medi...· 0 citations
The ISP index was positively associated with the risks of ACM and CVM among individuals with MASLD, but because it was constructed and internally evaluated within the same sample, its apparent predictive performance may be optimistic owing to overfitting.
Yan Chen, Kai-Ling Xie, Ning-Kun Xiao et al.· Lipids in Health and Disease· 0 citations
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global public health burden with progressive hepatic and cardiometabolic consequences. Insulin resistance is central to MASLD pathogenesis, and the triglyceride-glucose (TyG) index is a practical surrogate marker for insulin resistance...
S. Kang, N. Zhang, W. Chen et al.· European Heart Journal· 0 citations
FFM/FM ratio shows a universal protective effect against MASLD across sex and obesity strata, while WHR has sex-specific predictive value only in women.
Xia Tan, Xiao-Min Hou, Yuan Wen et al.· Frontiers in Public Health· 0 citations
BACKGROUND
Metabolic dysfunction-associated steatotic liver disease (MASLD) can occur in individuals who are not overweight or have obesity (normal-BMI MASLD), yet disease burden and management remain poorly characterized. We compared long-term outcomes and incretin-based therapy use between normal-BMI MASLD (nbMASLD)...
Isabel Casimiro, Aoi Agawa, Rachel Haide N. Tacata et al.· Journal of Clinical Endocrin...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.